Vol 19 No 1 (2013)

Vol 19 No 1 (2013)

Published January 2, 2013
https://doi.org/10.5912/jcb.v19i1

Commentary

Peter J. Pitts
The other side of innovation
Requires Subscription or Fee PDF
John Holland
Fixing a broken drug development process
Requires Subscription or Fee PDF

Articles

Chad Houston, J. Edward Graham, Peter Schuhmann
Biotechnology valuation and governance: Drug development and board of directors composition
Requires Subscription or Fee PDF
Clifford S Mintz, John Liu
China’s heparin revisited: What went wrong and has anything changed?
Requires Subscription or Fee PDF
Nirvana S. Pillay, Ramazan Uctu
A snapshot of the successful bio-clusters around the world: Lessons for South African biotechnology
Requires Subscription or Fee PDF
Brian Cordery
Use of medicines for carved out indications - Time for a change in approach?
Requires Subscription or Fee PDF
G. Steven Burrill
Improving IPO market still not an exit path
Requires Subscription or Fee PDF
Klaus Nickisch, Kerstin M Bode-Greuel
NPV modelling for the selection of value-creating biosimilar development candidates
Requires Subscription or Fee PDF

Legal and Regulatory Updates

Ewan Grist
EU Legal & Regulatory Update
Requires Subscription or Fee PDF